Thyroid Antibodies

Three principal autoantibodies are relevant to thyroid disease: thyroid peroxidase antibodies, thyroglobulin antibodies, and thyroid stimulating hormone receptor antibodies. The receptor antibodies are further subdivided into stimulating and blocking varieties according to their functional effect. Each has distinct clinical associations and applications.

Targeted use of these tests, according to the clinical question, makes thyroid disease evaluation efficient and cost effective. It avoids the diagnostic confusion and unnecessary cost of indiscriminate, non targeted antibody panel testing.

Classification and clinical associations

• Thyroid peroxidase antibodies are directed against the enzyme that iodinates thyroglobulin during thyroid hormone synthesis. They are the most sensitive marker for underlying autoimmune thyroid disease. They are positive in the great majority of patients with Hashimoto thyroiditis and in a substantial proportion of patients with Graves disease.
• Thyroid peroxidase antibodies are also present at low titre in a meaningful proportion of the general population without current or future clinically significant thyroid dysfunction. Isolated positive thyroid peroxidase antibodies without thyroid function abnormality therefore do not, by themselves, mandate treatment. They do support closer monitoring, given an increased future risk of progression to overt thyroid dysfunction.
• Thyroglobulin antibodies are directed against thyroglobulin itself. For autoimmune thyroid disease diagnosis they are less sensitive and specific than thyroid peroxidase antibodies.
• Thyroglobulin antibodies have a distinct, important application in follow up of differentiated thyroid cancer. Their presence can interfere with measurement of serum thyroglobulin and cause falsely low results. Serum thyroglobulin is used as a tumour marker for monitoring cancer recurrence after thyroidectomy.
• Always check thyroglobulin antibody status alongside thyroglobulin measurement in this follow up context, to interpret the thyroglobulin result correctly.
• Thyroid stimulating hormone receptor antibodies are the pathogenic autoantibody in Graves disease. They are predominantly stimulating, activating the receptor and driving the hyperthyroidism of Graves disease.
• A minority of patients, including some with Hashimoto thyroiditis, harbour blocking variants of this antibody class. These inhibit rather than stimulate receptor function and contribute to hypothyroidism.
• Standard clinical assays generally measure total thyroid stimulating hormone receptor antibody binding. In routine practice they do not distinguish the stimulating from the blocking functional subtype.

• Thyroid antibodies themselves produce no direct symptoms. Clinical features reflect the underlying thyroid functional status (hyperthyroid, hypothyroid, or euthyroid) and any associated extrathyroidal manifestations, rather than the antibody presence itself. Ophthalmopathy in thyroid stimulating hormone receptor antibody positive Graves disease is a particular example.
• Positive thyroid antibodies in an asymptomatic, biochemically euthyroid individual mark an underlying autoimmune predisposition and an increased future risk of overt thyroid dysfunction. They do not indicate current clinical disease requiring treatment.
• This distinction matters for counselling. It avoids unnecessary anxiety or treatment in this common scenario.
• Positive thyroid stimulating hormone receptor antibodies in a pregnant woman with current or past Graves disease carry specific additional relevance. These antibodies can pass transplacentally and affect fetal and neonatal thyroid function.
• This warrants specific consideration and, where relevant, monitoring during pregnancy and the neonatal period, addressed further under considerations specific to thyroid disease in pregnancy.

• Use thyroid peroxidase antibody testing to support the diagnosis of underlying autoimmune thyroid disease (particularly Hashimoto thyroiditis) in a patient with confirmed or suspected thyroid dysfunction. It also helps predict likelihood of progression in a patient with subclinical hypothyroidism.
• It is less appropriate as an isolated, standalone screening test in an asymptomatic individual with normal thyroid function testing. There, its clinical utility and the appropriate response to a positive result are more limited.
• Use thyroid stimulating hormone receptor antibody testing to confirm suspected Graves disease in a patient with biochemically confirmed hyperthyroidism.
• In pregnancy, use it to assess and guide monitoring for the risk of fetal or neonatal thyroid dysfunction in a woman with current or past Graves disease.
• Thyroglobulin antibody testing has a more limited standalone diagnostic role for autoimmune thyroid disease. It is an essential, mandatory accompanying test whenever serum thyroglobulin is measured for differentiated thyroid cancer surveillance, because it is critical to correct interpretation of the thyroglobulin result.
• Indiscriminate, non targeted testing of the full thyroid antibody panel, without a specific clinical question, is generally discouraged. It can generate results (particularly isolated, low titre positive results in an asymptomatic individual) that cause diagnostic confusion or unnecessary patient anxiety without informing management.
• This reinforces targeted, clinically indicated test selection over broad, unfocused panel testing.

• Management is directed at the underlying thyroid functional status and associated clinical condition identified (hyperthyroidism, hypothyroidism, or, where relevant, differentiated thyroid cancer surveillance). Follow the specific principles detailed under each of those conditions elsewhere. Antibody positivity alone is not a direct target for treatment.
• Isolated positive thyroid antibodies with normal thyroid function require no specific treatment. They may appropriately inform closer or more frequent monitoring of thyroid function over time, given the increased risk of future progression to overt dysfunction.
• This is particularly relevant in subclinical hypothyroidism with positive thyroid peroxidase antibodies. In pregnancy planning, baseline antibody status may inform anticipated monitoring needs during a subsequent pregnancy.
• Counsel the patient on the meaning and implications of a positive antibody result, distinguishing it from a diagnosis of active thyroid disease requiring treatment. This supports informed understanding and avoids unnecessary anxiety or requests for treatment in the common scenario of isolated antibody positivity without thyroid functional abnormality.